Internship

Intern – Environmental Health & Safety

Ehs

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$22 - $45Hourly

San Bruno, CA, USA

Paid internship at South San Francisco headquarters.

Category
Lab & Research
Environmental Sciences
Requirements
  • Currently enrolled in university, pursuing a Bachelor’s or Master’s Degree in Occupational Health & Safety, Public Heath, Industrial Safety, Industrial Hygiene, Environmental Engineering, Environmental Sciences, Chemical Engineering, Biological Sciences, or a related field
  • Strong analytical, quantitative, and problem-solving skills
  • Excellent communication and interpersonal skills
  • Ability to work independently and as part of a team
  • Basic knowledge of EHS regulations and standards is a plus
  • Proficiency in Microsoft Office Suite (Word, Excel, PowerPoint), Smart Sheet
Responsibilities
  • Support EHS Program Implementation by assisting with the development and implementation of EHS policies and procedures
  • Help ensure compliance with OSHA, EPA, and other relevant regulations by maintaining records and assisting in audits and inspections
  • Assist with the documentation and reporting of workplace incidents, near misses, and corrective actions
  • Support with updating EHS training content and employee training profiles
  • Help track and analyze EHS metrics, including incidents, safety observations, and waste management, and assist with preparing reports
  • Assist in performing risk assessments to identify potential hazards and implement measures to mitigate them
  • Assist in the development of EHS communications
  • Support ergonomic workspace evaluations
  • Assist with sustainability projects and initiatives

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

14%
Simplify Jobs

Simplify's Take

What believers are saying

  • Cytokinetics secured $575M funding from Royalty Pharma for drug development and commercialization.
  • Positive Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy.
  • Increased focus on personalized medicine aligns with Cytokinetics' targeted therapies.

What critics are saying

  • Competition from Bristol-Myers Squibb's Camzyos threatens Cytokinetics' market share for aficamten.
  • Reliance on successful clinical trials means negative results could impact financial stability.
  • High drug development costs could strain financial resources if returns are not realized.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
  • The company targets niche markets like hypertrophic cardiomyopathy and amyotrophic lateral sclerosis.
  • Cytokinetics has a robust pipeline, including drugs like omecamtiv mecarbil and aficamten.

Help us improve and share your feedback! Did you find this helpful?